Syndax CEO Sells Shares to Satisfy Tax Withholding on RSU Vesting
Syndax Pharmaceuticals Chief Executive Officer Michael A. Metzger sold 17,159 shares on February 9, 2026, at $21.028 per share to meet tax withholding obligations tied to vesting restricted stock units. The transaction reduced no material ownership contextually; Metzger still holds 491,690 shares as the company draws positive analyst attention and …